A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05865002|
Recruitment Status : Not yet recruiting
First Posted : May 18, 2023
Last Update Posted : May 18, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Relapsed Malignant Solid Neoplasm||Drug: AUR107||Phase 1|
|Study Type :||Interventional|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||Dose Escalation "3+3" Design|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)|
|Estimated Study Start Date :||June 2023|
|Estimated Primary Completion Date :||June 2025|
|Estimated Study Completion Date :||June 2027|
Experimental: AUR107, 5mg to 200mg
Currently, planned dose levels are 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD, 90 mg QD, 135 mg QD, and 200 mg QD
- First cycle Dose Limiting Toxicities (DLT) [ Time Frame: 28 days ]Assess dose limiliting toxicities of AUR107
- Safety of AUR107 as measured by the number of participants with treatment-related adverse events (AE) graded according to NCI CTCAE version 5.0 [ Time Frame: 28 days ]The assessment of safety was based on the frequency of deaths, AEs, SAEs, AEs leading to discontinuation of study drug, and abnormalities in specific clinical laboratory assessments. AEs and laboratory values will be graded for severity according to the NCI CTCAE version 5.0.
- Optimal Biological Dose [ Time Frame: 28 days ]Determine optimal Biological dose
- Pharmacokinetics: Maximum concentration (Cmax) [ Time Frame: Day 1 and Day 15 ]Maximum concentration of AUR107
- Pharmacokinetics: Time to Maximum concentration (Tmax) [ Time Frame: Day 1 and Day 15 ]Tmax in hours
- Pharmacokinetics: Area under the curve (AUC) [ Time Frame: Day 1 and Day 15 ]Area under the curve (AUC) of AUR 107 in h* mcg/mL
- Pharmacokinetics: Mean Residence Time (MRT) [ Time Frame: Day 1 and Day 15 ]Average time the drugs stays in the body
- Pharmacokinetics: Terminal elimination half-life [ Time Frame: Day 1 and Day 15 ]Terminal elimination half-life of AUR 107 in hours
- Maximum concentration (Cmax) administered under fasting/fed condition [ Time Frame: Day 8 and Day 9 ]Compare in fast and fed conditions
- Time to Maximum concentration (Tmax) administered under fasting/fed condition [ Time Frame: Day 8 and Day 9 ]Compare Tmax in fast and fed conditions
- Area under curve (AUC) administered under fasting/fed condition [ Time Frame: Day 8 and Day 9 ]Compare AUC in fast and fed conditions
- Exploratory endpoint: Identification of gene expression profiles [ Time Frame: Day 1, Day 2, and Day 15 ]Pharmacodynamic marker: Gene Expression profile as assessed by RNA analysis
- Exploratory endpoint- Efficacy assessments, Overall Response Rate [ Time Frame: Through study completion, an average of 1 year ]Efficacy assessments-Overall Response Rate
- Exploratory endpoint- Efficacy assessments, Duration of Response [ Time Frame: Through study completion, an average of 1 year ]Efficacy assessments- Duration of Response
- Exploratory endpoint- Efficacy assessments, Progression Free Survival (PFS) [ Time Frame: Through study completion, an average of 1 year ]Efficacy assessments- Progression Free Survival (PFS)
- Median Change from Baseline to End of Treatment in Tumor-Specific Markers, CA-125 in ovarian cancer [ Time Frame: Through study completion, an average of 1 year ]Change in Tumor Specific Markers - CA-125 in ovarian cancer
- Median Change from Baseline to End of Treatment in Tumor-Specific Markers, PSA in Castrate Resistant Prostate Cancer [ Time Frame: Through study completion, an average of 1 year ]Change in Tumor Specific Markers - PSA in Castrate Resistant Prostate Cancer
- Median Change from Baseline to End of Treatment in Tumor-Specific Markers, CEA in colorectal cancer [ Time Frame: Through study completion, an average of 1 year ]Change in Tumor Specific Markers - CEA in colorectal cancer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Males and females ≥ 18 years of age.
- Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
Acceptable bone marrow and organ function at screening as described below:
- ANC ≥ 1500/μL (without WBC growth factor support)
- Platelet count ≥ 100,000/μL without transfusion support
- Hemoglobin ≥ 9 g/dL (Transfusion is allowed to achieve this Hb)
- Total Bilirubin ≤ 1.5 x ULN; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN)
- AST (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases)
- ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases)
- Creatinine clearance (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula).
- Ability to swallow and retain oral medications.
- Histopathological diagnosis of a solid tumor. Note: The solid tumors must be in Stage IV at screening.
- Evidence of measurable disease per RECIST, v1.1 for solid tumors.
- Standard curative measures do not exist, and the patient must have exhausted all effective therapies available locally.
7a. At a minimum, solid tumor patients must have received at least two lines of systemic therapies in the metastatic incurable settings (these two lines must be in the metastatic setting and not in the earlier stage of cancer).
7b. Any cancer patient with access to any effective therapy must not be enrolled
Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from Cycle 1 Day 1 of the study.
Note: Concomitant use of low-dose prednisone (up to 10 mg/day) or medroxyprogesterone is allowed.
Note: Patients with CRPC (castrate-resistant prostate cancer) should continue to receive ongoing medical castration with LHRH analogs, and such patients are allowed.
- Presence of acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by NCI CTCAE v 5.0.
Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial)
• Use of any investigational agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
Use of drugs which are moderate / strong CYP3A4 inducers and/or drugs which are predominantly metabolized by CYP3A4 within 1week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
• Note: This class of drugs are also prohibited during DLT evaluation period and must be either avoided or used with caution beyond DLT evaluation period.
- Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) metastases. Patients with previously treated (> 6 months of screening) CNS metastases and are now stable and asymptomatic, from CNS perspective, are allowed.
- Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia).
- Patients with leukemia, myelodysplastic syndrome, multiple myeloma, or lymphoma.
- Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during the screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.
- Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
- Known active or chronic hepatitis B (HBsAg +ve) or hepatitis C infection (HCV antibody +ve).
- The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study.
- Uncontrolled congestive heart failure (New York Heart Association [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or transient ischemic attack, or pulmonary embolism within 3 months prior to Cycle 1 Day 1.
- Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in the past 3 months, before Cycle 1 Day 1.
- QTc (Bazzett) interval >460 ms on ECG at screening and/or at Cycle 1 Day 1 pre-dose.
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or clinically significant laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.
- Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of the person(s) with confirmed Covid-19 infection, at screening or Day 1 of Cycle 1.
- Positive pregnancy test for women of childbearing potential (WOCBP) at the screening or enrolment visit.
- Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods. (hormonal contraceptive, IUD, or any double combination of the male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05865002
|Contact: Suchit Kumbhare||+91 email@example.com|
|Contact: Suresh Oduru||+91 firstname.lastname@example.org|
|HCG City Cancer Centre|
|Vijayawada, Andhra Pradesh, India, 520002|
|Contact: Dr Lakshmi Priyadarshini +91 9966030988 email@example.com|
|Visakhapatnam, Andhra Pradesh, India, 530040|
|Unique Hospital Multispeciality and Research Institute|
|Surat, Gujarat, India, 395002|
|K R Hospital|
|Mysore, Karnataka, India, 570001|
|Grant Medical Foundation Ruby Hall Clinic|
|Pune, Maharashtra, India, 411001|
|Aurangabad, Maharastra, India, 431001|
|All India Institute of Medical Sciences|
|New Delhi, India, 110029|
|Contact: Dr. Deepam Pushpam +91 9650629370 firstname.lastname@example.org|
|Principal Investigator:||Akhil Kumar||Aurigene Oncology Limited|
|Responsible Party:||Aurigene Discovery Technologies Limited|
|Other Study ID Numbers:||
|First Posted:||May 18, 2023 Key Record Dates|
|Last Update Posted:||May 18, 2023|
|Last Verified:||May 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Relapse malignant neoplasm
Non small cell lung cancer